Abstract. The cell surface protein Transmembrane 4 L6 family member 1 (TM4SF1) has been detected in various tumors, and its expression on tumor cells is implicated in cancer cell metastasis and patient prognosis. The role of TM4SF1 in malignant tumors remains poorly understood, particularly in pancreatic cancer. We performed immunohistochemical staining to analyze the expression of TM4SF1 in resected pancreatic tissues and investigated the correlation between TM4SF1 expression and prognosis. The function of TM4SF1 in the invasion and migration of pancreatic cancer cells was analyzed in vitro using an RNA interference technique. In pancreatic cancer tissues, TM4SF1 expression was detected in cancer cells, and patients with high tumor levels of TM4SF1 showed longer survival times than those with low TM4SF1 levels (P=0.0332). In vitro, reduced TM4SF1 expression enhanced the migration (P<0.05) and invasion (P<0.05) of pancreatic cancer cells partially via decreased E-cadherin expression. TM4SF1 protein levels were also reduced after TGF-β1-induced epithelial-mesenchymal transition (EMT). TM4SF1 expression is associated with better prognosis in pancreatic cancer. Loss of TM4SF1 contributes to the invasion and migration of pancreatic cancer cells.
Introduction
Pancreatic cancer is one of the most deadly malignancies. In contrast to the stable or declining trends for most other cancer types, incidence rates are increasing for cancers of the pancreas (1) . Despite the use of multimodality treatment, the overall 5-year survival rate for pancreatic cancer is only six percent because of its high recurrence rate (1) . Invasion and metastasis are the major causes of the poor prognosis of pancreatic cancer (2) . The coordination of intercellular adhesion, cellmatrix interaction, matrix degradation, and cell migration is essential for cancer cell invasion and metastasis, and a diverse variety of transmembrane proteins regulate these cellular events (3) (4) (5) . Notably, proteins of the tetraspanin superfamily, such as Tspan8 (6) , CD82 (7), CD9 (8) , and CD151 (9) are important for the regulation of tumor cell motility and the interaction between tumor cells and their microenvironment. Therefore, tetraspanins may represent promising diagnostic or prognostic markers and therapeutic targets for tumor progression (10, 11) .
TM4SF1 is a member of the tetraspanin superfamily (12) . Tetraspanins are characterized by four transmembrane domains delimiting two extracytoplasmic regions of unequal size (13) . Elevated expression of TM4SF1 has been reported in several tumor types, and is implicated in cancer cell migration and patient outcome, but it adopts different roles that are dependent upon tumor type (14) (15) (16) (17) . In addition, TM4SF1 is important for endothelial cell migration and tumor angiogenesis (18, 19) , although the underlying mechanism of its function is not clear, especially in pancreatic cancer.
In the present study, we investigated the role of TM4SF1 in pancreatic ductal adenocarcinoma (PDAC). TM4SF1 expression in PDAC tissues was evaluated by immunohistochemistry, and the correlation between clinicopathological characteristics and TM4SF1 expression was assessed to determine its prognostic significance in PDAC. gated changes in cell migration and invasion in vitro using a siRNA knockdown approach.
Materials and methods
Cell lines. The following six pancreatic cancer cell lines were used: KP-2, SUIT-2 (Dr H. Iguchi, National Shikoku Cancer Center, Matsuyama, Japan), MIA PaCa-2 (Japanese Cancer Resource Bank, Tokyo, Japan), Capan-1, Capan-2 and Hs766T (American Type Culture Collection, Manassas, VI, USA). The human immortalized pancreatic ductal epithelial cell line (HPDE6-E6E7 clone 6) was kindly provided by Dr Ming-Sound Tsao (University of Toronto, Toronto, Canada). All cells were maintained as previously described (20) . 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR).
One-step real-time qRT-PCR using gene-specific primers was performed as described previously (23) . Primer sequences were as follows: TM4SF1 forward 5'-ATTGGAAT TGCAGGATCTGG-3' and reverse 5'-GCCGAGGGAATCAA GACATA-3'; 18S rRNA forward 5'-GTAACCCGTTGAACC CCATT-3' and reverse 5'-CCATCCAATCGGTAGTAGCG-3'. BLAST searches were performed to ensure the specificity of all primers. Primers were purchased from Sigma Genosys (Tokyo, Japan).
Immunohistochemical procedures and evaluation. Immunohistochemistry was performed using a Histofine SAB-PO kit (Nichirei, Tokyo, Japan) (24) . Sections were incubated with anti-TM4SF1 antibody (HPA002823; Sigma-Aldrich, Tokyo, Japan) overnight at 4˚C. Carcinoma cells were identified according to morphology and counted in at least 20 fields per section at x200 magnification. The distribution of TM4SF1 staining was evaluated as the percentage of stained cells, and was scored as follows: 0, no staining or <10%; 1, 11-25%; 2, 26-50%; 3, 51-75%; or 4, 76-100%. Cells were also scored for staining intensity, which was scored as 0, no staining; 1, weak; 2, moderate; or 3, strong. The multiplication product (from 0-12) from these two scores was used to assign patients into one of two groups according to TM4SF1 expression, where a score of 0-4 represented low expression and a score of 6-12 represented high expression. All slides were evaluated independently by two investigators who were unaware of the clinical features of each case.
Silencing of TM4SF1 using small interfering RNAs (siRNAs).
Gene silencing was carried out using siRNA (Qiagen, MA, USA) directed against human TM4SF1. Sequences were as follows: siRNA-1 (sense, 5'-ggaccacuaugucuugauutt-3'; antisense, 5'-aaucaagacauaguggucctt-3'); siRNA-2 (sense, 5'-cgaug acugggcaagaagatt-3'; antisense, 5'-ucuucuugcccagucaucgta-3').
Qiagen all-star siRNA was used as a negative control. Transfections were performed as described previously (25). All cells were used in subsequent experiments 48 h after transfection.
Matrigel invasion and migration assays.
Migration and invasion of cultured cancer cells were assessed by counting the number of cells migrating or invading through uncoated or Matrigel-coated transwell chambers (BD Biosciences, Franklin Lakes, NJ, USA) as described previously (20, 26) . Cells were maintained in 10% FBS/DMEM during these assays. Cells were transfected with siRNAs 48 h prior to experimentation. Migration was determined after a 24-h period, and invasiveness was determined after a 48-h period.
TGF-β1 treatment. SUIT-2 and Capan-2 cells were cultured in 6-well plates (1x10 5 cells/well) in 1% FBS/DMEM with or without 10 ng/ml recombinant human TGF-β1 (R&D, Oxon, UK) for 24 and 48 h (27) . At each time-point, total RNA was extracted to evaluate TM4SF1 mRNA expression by qRT-PCR. To evaluate TM4SF1 protein levels, cells were seeded in 90-mm dishes at a density of 2x10 5 cells/dish and cultured in 1% FBS/DMEM with or without 10 ng/ml TGF-β1 prior to cell lysis.
Western blot analysis. Western blotting was performed as described previously (28) . Antibodies used in this study were as follows: anti-TM4SF1 (sc-103267; Santa Cruz, CA, USA), anti-E-cadherin (no. 3195), anti-vimentin (no. 5741), anti-N-cadherin (no. 4061), anti-claudin-1 (no. 4933) (Cell Signaling Technology, Danvers, MA, USA) and anti-β actin (ab8227; Abcam, Cambridge, MA, USA).
Statistical analysis. A χ
2 test was used to analyze the correlation between TM4SF1 expression and clinicopathological characteristics. Survival analysis was performed using Kaplan-Meier analysis and curves were compared using the log-rank test. For in vitro experiments, values are expressed as means ± standard deviation. Comparison between two groups was performed using the Student's t-test. Statistical significance was defined as P<0.05. All statistical analyses were performed using JMP 9.0.2 software (SAS Institute, NC, USA).
Results

Pancreatic cancer cells express TM4SF1.
We first sought to determine the level of TM4SF1 expression in PDAC and normal pancreatic tissues. In normal pancreatic tissues, weakto-no staining was detected in pancreatic ductal epithelial cells and TM4SF1 expression was not observed in acinar cells or stroma. Blood vessels consistently stained positive for TM4SF1, and were used as a positive control (Fig. 1A-a  and -c) . In tumor tissues, strong luminal membrane surface staining and a weak-to-moderate cytoplasmic staining was detected in cancer cells (Fig. 1A-b) . In addition to tumor tissue samples where moderate staining was observed, there were also tumor tissue samples where little-to-no staining was observed (Fig. 1A-c) .
Prognostic significance of TM4SF1 expression. Survival analysis was performed for patients with PDAC. The high TM4SF1 expression group showed better survival (P=0.0332; Fig. 1B ) than the low expression group, and there was an obvious difference in the disease-free time between the groups (P=0.0409; Fig. 1B ). Median survival was 30 months for the high expression group and 17 months for the low expression group (Table II) . Next, we performed multivariate analysis based on the Cox proportional hazard model on all parameters that were found to be significant in the univariate analyses. Overall survival was significantly dependent on residual tumor (R1) status (relative risk = 2.732, P=0.0017), vascular invasion (relative risk = 2.461, P=0.0101) and low TM4SF1 expression (relative risk = 1.987, P=0.0196) (Table III) . The relationship between TM4SF1 expression and clinicopathological factors of PDAC is shown in Table IV . There was no statistically significant correlation between TM4SF1 expression and clinicopathological factors possibly due to the relatively small size of the patient cohort, although it appears that the patients with low expression have a higher tumor grade and a more advanced clinical stage. Because there was an obvious difference in the disease-free time, we analyzed the site of first recurrence (Fig. 1C) and found that the locoregional recurrence rate in the low TM4SF1 expression group (28.21%) was higher than in the high expression group (5.71%; P=0.0079) although the total recurrence rates for the two patients groups were similar (Table V) . The data suggest that tumors with low TM4SF1 expression undergo local spread more frequently than those with high expression, and this may contribute to the observed survival differences.
Inhibition of TM4SF1 expression promotes migration and invasion of pancreatic cancer cells.
We also determined the level of TM4SF1 expression in a variety of pancreatic cancer cell lines, and the level of TM4SF1 mRNA expression was found to be higher in pancreatic cancer cell lines than in normal (HPDE) epithelial cells ( Fig. 2A) . Because local tumor invasion is more likely in patients with low TM4SF1 tumor expression, and because TM4SF1 has been reported to be involved in the migration of cancer cells (14, 15) , we next performed migration and invasion assays following knockdown of TM4SF1 in pancreatic cancer cells. Decreased TM4SF1 protein expression was confirmed by western blotting following transfection of cells with TM4SF1-specific siRNA (Fig. 2B) . The invasion and migration of two cell lines studied, SUIT-2 and Capan-2, were enhanced following siRNA-mediated knockdown of TM4SF1 (Fig. 2C) . These suggest that TM4SF1 has an inhibitory role in the invasion and migration of pancreatic cancer cells.
E-cadherin expression is reduced in pancreatic cancer cells following knockdown of TM4SF1.
Because the process of cancer invasion requires epithelial tumor cells to undergo epithelial to mesenchymal transition (EMT) either transiently or stably (29), we examined the correlation between the expression of TM4SF1 and EMT markers in vitro. We found that E-cadherin expression was reduced after knockdown of TM4SF1, but there were no changes in the expression of other makers including vimentin, N-cadherin and claudin-1 (Fig. 3A) . Changes in cell morphology, however, were not observed after knockdown of TM4SF1 (data not shown). TGF-β1 negatively regulates TM4SF1 expression. TGF-β1 is a major inducer of EMT in a number of cellular contexts (30) , and plays a pivotal role in driving EMT in the pathogenesis of pancreatic cancer (27, 31) . To investigate whether TGF-β1 influences TM4SF1 expression, we performed additional in vitro analyses on pancreatic cancer cells treated with TGF-β1. Western blot analysis revealed that TGF-β1 treatment significantly downregulated E-cadherin expression and upregulated vimentin expression in both these cell lines. TM4SF1 protein levels were also reduced following treatment with TGF-β1 for 48 h (Fig. 3B) .
Discussion
TM4SF1 is a tumor-associated antigen that is detected widely in human carcinomas (32) , and it represents a promising target for antibody-mediated immunotherapy (33) . However, the exact role of TM4SF1 in cancer remains controversial. TM4SF1 is reported to be a prognostic marker in a number of malignant tumors. In lung (14) and colorectal cancer (34) patients, increased expression of TM4SF1 was shown to be significantly associated with early postoperative relapse and shorter survival. In contrast, our study revealed that decreased expression of TM4SF1 was significantly associated with shorter survival and early local spread in PDAC patients, suggesting that TM4SF1 plays an inhibitory role in pancreatic cancer relapse and tumor progression. These results are consistent with those of a previous study of TM4SF1 in mesothelioma patients (16) . Furthermore, serial analysis of gene expression in breast cancer tissues revealed a negative correlation between TM4SF1 expression and progression of breast carcinomas (17) . These data suggest that TM4SF1 may be a novel predictive marker of good prognosis in several tumors including PDAC, although the clinical significance of TM4SF1 expression varies depending on tumor type.
With respect to the cellular functions of TM4SF1, it has previously been reported that high expression of TM4SF1 increases the invasiveness of lung carcinoma cells (14) and the migration of prostate cancer cells (15) . Our study demonstrates a contrasting function for TM4SF1 in pancreatic cancer cells as cancer cell motility was enhanced following inhibition of TM4SF1 expression, a finding which may account for the differences in local recurrence rate and prognosis among PDAC patients. Furthermore, we found that knockdown of TM4SF1 reduced E-cadherin expression in pancreatic cancer cells (although other EMT markers examined were unaffected) and that treatment with TGF-β1 downregulated TM4SF1 in these cells. E-cadherin is closely implicated in the motility of cancer cells (35) , and loss of E-cadherin expression is associated with poor clinical outcome in several cancer types (36, 37) including pancreatic cancer (38) . Our findings therefore suggest a role for TM4SF1 in TGF-β1-induced EMT, and that TM4SF1 may alter the migration of pancreatic cancer cells partially via regulating E-cadherin expression. Targeting TM4SF1 expression may therefore potentially lead to the development of promising therapies for several types of tumor, including PDAC.
Previous reports indicate that tetraspanins, through protein-protein and protein-lipid interactions, recruit various transmembrane and cytoplasmic proteins to form tetraspaninenriched microdomains (TERM), functional complexes involved in cell migration (39) . Tetraspanins interact with a variety of transmembrane proteins, participate in various TERM formations, and can perform different functions in a variety of cell types. For example, CD151, one of the tetraspanin members, regulates cell migration in a cell typespecific manner (40) . The CD151-α6β4 complex is a major component of hemidesmosomes in skin keratinocytes, structures that oppose cell migration by stabilizing cell attachment to the extracellular matrix (41) . However, in human cervical carcinoma cells, CD151 promotes tumor cell migration but does not appear to affect cell adhesion to matrix proteins (42) . TM4SF1 is also associated with TERM, and influences cell motility via regulating the surface presentation and endocytosis of a number of components of these complexes (43) . Therefore, we speculate that in diverse tissues or cell types, TM4SF1 may interact with different transmembrane proteins (such as E-cadherin) and influence cell migration by modulating the endocytosis and recycling of proteins associated with motility.
In conclusion, our results suggest that TM4SF1 plays an inhibitory role in the migration and invasion of pancreatic cancer cells. Further investigation is now needed to elucidate the mechanisms of interaction between TM4SF1 and either E-cadherin or TGF-β1 in the migration and invasion of pancreatic cancer cells. Furthermore, decreased expression of TM4SF1 is significantly associated with shorter survival in PDAC patients, suggesting that TM4SF1 is a promising prognostic biomarker in PDAC.
